Teachers Advisors LLC boosted its position in Luminex Co. (NASDAQ:LMNX) by 0.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 294,425 shares of the medical instruments supplier’s stock after buying an additional 1,642 shares during the quarter. Teachers Advisors LLC’s holdings in Luminex were worth $8,924,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in LMNX. Vanguard Group Inc lifted its stake in shares of Luminex by 4.8% in the 3rd quarter. Vanguard Group Inc now owns 4,268,240 shares of the medical instruments supplier’s stock valued at $129,370,000 after acquiring an additional 194,226 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Luminex by 4.8% in the 3rd quarter. Vanguard Group Inc. now owns 4,268,240 shares of the medical instruments supplier’s stock valued at $129,370,000 after acquiring an additional 194,226 shares during the last quarter. Morgan Stanley lifted its stake in shares of Luminex by 12.1% in the 3rd quarter. Morgan Stanley now owns 176,764 shares of the medical instruments supplier’s stock valued at $5,357,000 after acquiring an additional 19,093 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Luminex by 7.2% in the 3rd quarter. Legal & General Group Plc now owns 98,076 shares of the medical instruments supplier’s stock valued at $2,964,000 after acquiring an additional 6,627 shares during the last quarter. Finally, Glenmede Trust Co. NA lifted its stake in shares of Luminex by 200,517.2% in the 3rd quarter. Glenmede Trust Co. NA now owns 756,327 shares of the medical instruments supplier’s stock valued at $22,923,000 after acquiring an additional 755,950 shares during the last quarter. 83.77% of the stock is owned by institutional investors and hedge funds.
A number of research firms have recently weighed in on LMNX. BidaskClub lowered Luminex from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 22nd. Zacks Investment Research raised Luminex from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. ValuEngine raised Luminex from a “buy” rating to a “strong-buy” rating in a research note on Monday, October 29th. Citigroup lowered their target price on Luminex from $34.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, November 6th. Finally, TheStreet lowered Luminex from a “b-” rating to a “c+” rating in a research note on Friday, December 14th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $28.40.
Shares of NASDAQ:LMNX opened at $24.98 on Friday. Luminex Co. has a 1 year low of $18.62 and a 1 year high of $35.37. The stock has a market cap of $1.11 billion, a P/E ratio of 27.45, a price-to-earnings-growth ratio of 3.07 and a beta of 0.67.
Luminex (NASDAQ:LMNX) last announced its quarterly earnings results on Monday, November 5th. The medical instruments supplier reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.03). Luminex had a net margin of 5.65% and a return on equity of 5.99%. The business had revenue of $72.40 million for the quarter, compared to analysts’ expectations of $74.05 million. During the same quarter in the prior year, the firm earned $0.13 EPS. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. As a group, equities analysts forecast that Luminex Co. will post 0.58 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, January 10th. Investors of record on Thursday, December 20th were issued a dividend of $0.06 per share. The ex-dividend date was Wednesday, December 19th. This represents a $0.24 dividend on an annualized basis and a yield of 0.96%. Luminex’s dividend payout ratio is presently 26.37%.
COPYRIGHT VIOLATION NOTICE: “Teachers Advisors LLC Purchases 1,642 Shares of Luminex Co. (LMNX)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2019/01/12/teachers-advisors-llc-purchases-1642-shares-of-luminex-co-lmnx.html.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.
Read More: What is a Fiduciary?
Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.